Humacyte, Inc.

NASDAQ:HUMA

Biotechnology

Healthcare
$0.50 -3.35%

-$0.03 today

Market cap
$138.90M
Beta
2.46
P/E (TTM)
-1.9
EPS (TTM)
-$0.49
52W Low $0.55High $2.84

Volume 3.91M

Average 8.14M

HUMA Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Humacyte, Inc.NASDAQ: HUMA

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income turns negative

Q1 FY2026 net income was -$17.62M, compared with $39.14M a year earlier. Trailing-twelve-month net income was -$97.59M. Over 3 fiscal years it compounded at +50.6% a year.

Context

  • Net income amounted to 2003.6% of revenue in FY2025.
  • Net income grew in size in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of -$91.99M (+125.3%) for the fiscal year ending Dec 2026, a step up from the -72.5% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$17.62M-29.0% QoQ
Last fiscal yearDec 2025
-$40.83M-72.5% YoY
LTMMar 2026
-$97.59M+25.7% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-145.0%-16.3%+128.7 pp
1 year-72.5%+125.3%+197.8 pp
3-year CAGR+50.6%-5.0%-55.5 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(40.83M) USD
Year-over-year change
+72.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How HUMA compares with its peers on the latest reported figures

  • HUMA's LTM Mar 2026 net income of $97.59M is the 5th largest of the 11 companies compared; the peer median is $77M.
  • Its year-over-year change of +25.7% is the 3rd highest of 11, against a peer median of +3.1%.
  • Net income amounts to 4840.8% of revenue for HUMA, versus a peer median of 266.9%.
HUMA Competitors Peer median
Net Income for HUMA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$239.55M +441.4%—110.0%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$169.52M +21.5%+11.0%—
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$166.12M -770.3%+15.0%2895.1%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$116.64M +37.7%+37.1%319.6%
HUMAHumacyte, Inc.LTM Mar 2026$97.59M +25.7%+50.6%4840.8%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$78.67M +15.4%—173.5%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$75.32M -6.4%-12.0%266.9%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$57.09M -16.9%+0.6%—
IMRXImmuneering CorporationLTM Mar 2026$54.44M -11.9%+3.5%—
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$51.99M +12.6%+8.9%—
SGMTSagimet Biosciences Inc.LTM Mar 2026$43.51M -23.8%+18.7%—
Peer median (excluding HUMA) $77M+3.1%+9.9%266.9%

Competitors are the stored peer set for HUMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(26.48M)(11.97M)(110.78M)(148.7M)(40.83M)
Depreciation & Amortization8.24M8.21M7.72M7.19M5.33M
Deferred Income Tax00000
Stock-Based Compensation10.15M6.18M6.83M6.14M9.75M
Change in Working Capital(557K)1.03M6.57M311K(23.4M)
Accounts Receivables(63K)145K31K0(261K)
Inventory0000(21.83M)
Accounts Payables(197K)(509K)4.81M(1.96M)973K
Other Working Capital(297K)1.39M1.73M2.27M(2.28M)
Other Non-Cash Items(72.54M)(74.59M)16.35M36.94M(55.9M)
Operating Cash Flow(81.19M)(71.13M)(73.31M)(98.12M)(105.04M)
Capital Expenditures(220K)(1.05M)(2.28M)(1.57M)(884K)
Acquisitions (Net)00000
Purchases of Investments(8M)(10.11M)000
Sales of Investments016M2.11M00
Other Investing Activities00000
Investing Cash Flow(8.22M)4.85M(173K)(1.57M)(884K)
Debt Repayment27.93M(1.98M)5.7M(2.58M)36.39M
Common Stock Issued598K535K566K45.93M113.44M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities239.05M535K(1.76M)27.71M(88.34M)
Financing Cash Flow266.98M(1.45M)4.51M114.18M61.49M
Effect of Forex Changes00(209K)00
Net Change in Cash177.57M(67.73M)(69.18M)14.49M(44.44M)
Free Cash Flow(81.41M)(72.18M)(75.59M)(99.69M)(105.93M)

Humacyte, Inc.

NASDAQ:HUMA

Intrinsic Alpha fair value

Locked

Current Price

$0.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.